|
pSiVida Limited - Comparative Business Analysis Snapshot
Business Description
pSiVida Limited. The Group's principal activity is engaging in the research and development of drug delivery products, initially in ophthalmology and oncology. It owns and licenses biomaterial and drug delivery patents granted in the United States and Europe such as Durasert, BioSilicon and CODRUG. Its products include Vitasert, a drug implant for the treatment of AIDS-related Cytomegalovirus Retinitis; Retrisert, an intravitreal drug implant for the treatment of chronic non-infectious Uveitis; and Medidur, which is currently in Phase III clinical trials for the treatment of Diabetic Macular Edema. It also has pre-clinical development products for the treatment of age-related macular degeneration and retinitis pigmentosa. The Group has operations in the United Kingdom, Australia, Singapore and the United States, and has partnership collaborations with Chiron Vision Corp, Bausch & Lomb Inc, Alimera Sciences and Pfizer. The Group is headquartered in Perth, Western Australia.
Competitor Analysis
This analysis compares pSiVida Limited with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
